Nontuberculous mycobacterial (NTM) lung disease is a chronic, progressive condition caused by nontuberculous mycobacteria. NTM lung disease occurs more frequently in older adults and people with other lung diseases, like bronchiectasis, and chronic obstructive pulmonary disease (COPD).
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2
If you or someone in your family has asthma and is going away on vacation, it is important to create a checklist to ensure that the necessary research has been done and all of the necessary items are brought with you to your destination!
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
If you or someone in your family has asthma and is going away on vacation, it is important to create a checklist to ensure that the necessary research has been done and all of the necessary items are brought with you to your destination!
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
Bronchiectasis – How Key is the Role of Airway Clearance? A Practical Review and Guide for this Pandemic and Beyond
Join Professor James Chalmers, Pamela Vaughn and Paul McCallion as they discuss the importance of airway clearance therapy in Bronchiectasis patients, global guidelines and recommendations during the pandemic.
Est-ce une MPOC, une Fibrose, de l’Asthme…NON, C’est une bronchiectasie! Plein feux sur une meilleur prise en charge de cette pathologie!
Joignez-vous à Isabelle LeClerc, Infirmière praticienne, pour une discussion accréditée sur la bronchiectasie afin d'en savoir plus sur ce qui rend cette maladie respiratoire unique. Ensemble, nous découvrirons comment vous pouvez aider vos patients atteints de bronchiectasie à mieux respirer grâce à une approche non-pharmacologique ainsi qu’une bonne autogestion pour finalement améliorer leur qualité de vie.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
While the hot summer months may affect the everyday management of your lung health, it doesn’t have to keep you from living your fullest life. Here are a few tips to help you find the breathing spaces you need this summer.
Accelerate and scale your digital Metered Dose Inhaler (MDI) portfolio programs with the trusted Top Mounted Actuation Indicator (TMAI) technology platform.
The prototype AeroChamber2go* spacer device was preferred by patients compared to the A2A† spacer and provides a good option for patients currently using the Metered Dose Inhaler without a spacer while on-the-go.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
The widely differing inspiratory flow profiles from Turbuhaler† DPI contributed to greater variability in delivered dose to the carina.
MDI delivery via the AeroChamber Plus* Flow-Vu* VHC resulted in significantly increased mass to the carinal region irrespective of inhalation maneuver as well as reduced oropharyngeal deposited mass which in vivo is likely to result in reduced throat irritation or thrush in the mouth and throat.
Manage asthma during wildfires by monitoring air quality, indoor cleanliness, limiting outdoor exposure, wearing masks, consulting healthcare providers, and optimizing medication with AeroChamber VHC* and AeroChamber 2Go*.
Have you ever struggled with chest congestion or a buildup of mucus in your chest? If so, you're not alone. Many people experience these uncomfortable symptoms, which can be caused by a variety of factors such as the common cold, allergies, asthma or COPD. The article below explores the role of mucus in chest congestion and discuss some ways to clear your airways.
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
This article describes the generative, patient-centered, design process used in the development of a prototype VHC intended primarily for use ‘on the go’ by adults with persistent asthma or newly diagnosed COPD.
Medication delivery can vary significantly depending on the pMDI/spacer system which will have implications on the carbon footprint. In this case, the use of the AeroChamber Plus* Flow-Vu* spacer could potentially reduce the carbon footprint by up to five-fold compared to other spacers.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
Manage asthma during wildfires by monitoring air quality, indoor cleanliness, limiting outdoor exposure, wearing masks, consulting healthcare providers, and optimizing medication with AeroChamber VHC* and AeroChamber 2Go*.
